[18F]AlF-NOTA-PCP2 PET/CT to Assess PD-L1 Status in Head and Neck Cancer
[18F]AlF-NOTA-PCP2 PET/CT provides a superior, noninvasive approach for evaluating PD-L1 expression in HNC. Its high specificity for PD-L1 and favorable biodistribution position it as a promising tool for monitoring immunotherapy responses and informing treatment decisions.
Authors
- Bohan Zhang (ORCID: https://orcid.org/0000-0002-0066-2755)
- Man Hu (ORCID: https://orcid.org/0000-0003-4409-286X)
- Jianxin Shi (ORCID: https://orcid.org/0000-0002-7717-0863)
- Zhe‐Sheng Chen (ORCID: https://orcid.org/0000-0002-8289-097X)
- Kewen He (ORCID: https://orcid.org/0000-0003-0068-7191)
- Dong‐Fang Meng (ORCID: https://orcid.org/0000-0001-9840-1133)
- Shijie Wang (ORCID: https://orcid.org/0000-0002-3135-1343)
- Yang Li (ORCID: https://orcid.org/0000-0001-9612-2704)
- Yong Wang (ORCID: https://orcid.org/0000-0002-2244-1742)
- Zhiguo Liu (ORCID: https://orcid.org/0000-0001-7114-1810)
- Jinming Yu (ORCID: https://orcid.org/0000-0001-5933-9912)
- Xingchen Ding (ORCID: https://orcid.org/0000-0002-4229-5340)
- Kai Teng (ORCID: https://orcid.org/0000-0002-5782-1307)
Institutions
- St. John's University (US)
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1097/rlu.0000000000006151
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00